期刊文献+

替吉奥联合紫杉醇周疗对晚期老年胃癌患者的临床疗效评价 被引量:8

Clinical evaluation of S-1 capsule combined with weekly Paclitaxel on elderly patients with advanced gastric cancer
下载PDF
导出
摘要 目的 评价替吉奥(S-1)联合紫杉醇周疗治疗晚期老年胃癌患者的近期疗效及毒副反应物.方法 将广西横县人民医院确诊的38例晚期老年胃癌患者随机分为2组,治疗组20例,采用紫杉醇联合替吉奥化疗:紫杉醇60 mg/m2,第1、8、15 d用药,替吉奥胶囊80 mg/m2,2次/d,连续口服14 d,28 d为1个周期;对照组18例,采用FP方案:顺铂15 mg/m2,第1~5天静点,5-Fu 750mg/m2,第1~5天静点,28 d为1个周期.两组患者至少治疗2个周期后评价其疗效及毒副反应.结果 治疗组与对照组的有效率(RR)、疾病控制率(DCR)、1年生存率分别为40.0%、75.0%、55.0%和22.2%、50.0%、38.9%,差异无统计学意义(P>0.05);治疗组患者KPS改善情况优于对照组(P<0.05);治疗组的胃肠道反应及Ⅲ~Ⅳ度骨髓抑制明显低于对照组(P<0.05).结论 替吉奥口服联合紫杉醇周疗方案化疗有效率高,老年患者耐受性好,是老年晚期胃癌患者值得选择的化疗方案. Objective To evaluate the efficacy and toxicity of S-1 capsule combined with weekly Paclitaxel on elder- ly patients with advanced gastric cancer. Methods Thirty-eight etderly patients of gastric cancer diagnosed in People' s Hospital of Heng County were randomly divided into two groups. Treatment group of 20 patients were received Paclitaxel combined with S-1 chemotherapy (the chemotherapy included Paclitaxel 60 mg/m2 intravenously on days 1, 8, 15 and S-1 capsule 80 mg/m2 twice daily for 14 days, every 28 days repeated). The control group of 18 patients were received FP chemotherapy (the chemotherapy included Cisplatin 15 mg/m2 intravenously every day from the first day to fifth day, Fluorouraeil 750 mg/m2 intravenously every day from first day to fifth day, every 28 days repeated). Efficacy and toxici- ty were evaluated at least 2 cycles of treatment between two groups. Results The efficiency of the treatment group and control group were 40.0% , 22.2% , the disease control rates were 75.0% , 50.0% , the 1-year survival rates were 55.0% , 38.9% (P 〉0.05). Quality of life of treatment group was better than that of the control group (P 〈 0. 05). The gastrointestinal reaction and Ⅲ-Ⅳ bone marrow suppression of the treatment group were significantly lower than the control group (P 〈 0.05). Conclusion The chemotherapy of S-1 combined with weekly Paclitaxel is efficient. Eld- erly patients could tolerate this treatment. It is valuable chemotherapy for elderly patients with advanced gastric cancer.
作者 黄法声
出处 《胃肠病学和肝病学杂志》 CAS 2014年第12期1420-1422,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 替吉奥 紫杉醇 胃癌 化疗 老年人 S-I Paclitaxel Gastric cancer Chemotherapy Elderly
  • 相关文献

参考文献8

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [ J ]. CA Cancer J Clin, 2005, 55(2) : 74-108.
  • 2陈智伟,廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用[J].中国肿瘤,2004,13(10):616-618. 被引量:174
  • 3Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials [ J]. J Clin Oncol, 2004, 22( 1 ) : 19-22.
  • 4Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggre- gate data [J]. J Clin Oncol, 2006, 24(18): 2903[J]. 2909.
  • 5Koizumi W, Akiya T, Sato A, et al. Phase Ⅱ study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study [ J ]. Cancer Chemother Pharmacol, 2010, 65 (6) : 1093-1099.
  • 6Lee SJ, Cho SH, Yoon JY, et al. Phase Ⅱ study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer [ J]. Cancer Che- mother Pharmacol, 2009, 65 ( 1 ) : 159-166.
  • 7王竞,王金万.胃癌治疗进展[J].癌症进展,2004,2(2):88-93. 被引量:37
  • 8Hokita S, Aikou T, Miyazono F, et al. A phase I combination chem- otherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer [ J ]. Cancer Chemother Pharmacol, 2006, 57(6) : 736-740.

二级参考文献33

  • 1WHO handbook for reporting results of cancer treatment [M].Geneva (Switzerland):World Health Organization,1979.
  • 2Duffaud F,Therasse P.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer,2000,87(12):869-870.
  • 3James K,Eisenhauer E,Christian M,et al.Measuring response in solid tumors:unidimensional versus bidimensional measurement[J].J Natl Cancer Inst,1999,91(6):523-528.
  • 4Mazumdar M,Smith A,Schwartz LH.A statistical simulation study finds discordance between WHO criteria and RECIST guideline[J].J Clin Epidemiol,2004,57(4):358-365.
  • 5Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors [J].J Natl Cancer Inst,2000,92(3):179-181.
  • 6Werner-Wasik M,Xiao Y,Pequignot E,et al.Assessment of lung cancer response after nonoperative therapy:tumor diameter,bidimensional product,and volume.A serial CT sean-based study[J].Int J Radiat Oncol Biol Phys,2001,51(1):56-61.
  • 7Prasad SR,Saini S,Sumner JE,et al.Radiological measurement of breast cancer metastases to lung and liver:comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines [J].J Comput Assist Tomogr,2003,27(3):380-384.
  • 8Trillet-Lenoir V,Freyer G,Kaemmerlen P,et al.Assessment of tumour response to chemotherapy for metastatic coloreetal cancer:accuracy of the RECIST criteria[J].BrJ Radiol,2002,75(899):903-908.
  • 9[1]Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer:Epidemiology, pathology and treatment. Annals of Oncology,2003, 14 (Suppl 2) :ii31
  • 10[2]Frederick LG, David LP, Irvin DF, et al. AJCC Cancer Staging Manual. 6th. ed, New York: Springer, 2002, 99

共引文献208

同被引文献46

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部